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Abstract. The aim of this paper is to discuss the competitive effects of the private equity 
industry in emerging industries, with a focus on the Dutch Life Sciences cluster located in 
West Holland, a Dutch region. As this analysis shows, the circumstances which favored the 
early success of this industry include factors such as education, infrastructure, 
governmental support, the existence of key industrial players, as well as the investment 
strategies of private actors. What this paper underline is the significant influence of private 
equity investments for the financial support of innovative products, on one side, and the 
growing opportunities through, on the other side. The paper is structured in two parts. The 
first reviews the literature regarding the evolution of emerging industries and the impact 
of geographic locations on their attractiveness to private investors. The second part 
highlights the way in which an emerging industry (i.e. life sciences industry in West Holland 
region) has upgraded its competitive advantage under the influence of private capital.  
 
Keywords: agglomeration; clusters; private equity; venture capital; emerging industries; 
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Introduction  
 
The emergence of new, high-growth sectors is, along with disruptive ideas or 
reconfiguration of value chains, one of the strongest determinants shaping the 
competitive landscape these days (Russo, 2003). Globalization and the development of 
technologies led to the transformation of new business models, based on disruptive 
ideas, with high-growth rates of sectors by being supported by the competition and 
cooperation between industrial and technological firms. Creativity also conducts the 
development of these sectors, which often take the social challenges regarding the 
environment, through eco-innovative solutions and efficient use of resources. 
 
The emerging industries take advantage of location-specific opportunities in terms of 
specialization and diversification, and they are more advanced in those regions which 
host a significant portfolio of traditional sectoral clusters (European Cluster 
Observatory, 2016).  Since clusters are the intersection points between cooperation and 
competitiveness, they have significant effects over the local, regional, national or even 
international economies (Porter, 1998). The more sophisticated the competition arise, 
through rising of knowledge and innovation, the more important the geographic 
agglomeration become. 
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Generally, these industries require significant research and development funds, and due 
to their innovative products, private investors are attracted to join and to financially 
support them, despite the lack of information about market conditions. As the companies 
grow and the investors achieve their financial targets, these mature private equity-
backed companies help the whole industry to develop. 
 
This paper attempts to highlight the role of emerging industries for creating competitive 
advantage under the influence of private equity. This virtuous circle of entrepreneurship 
helps industries develop at higher than average rates and take advantage not only of the 
capital inflows but of the accompanying business and industry expertise as well. 
 
In the following, I will subject to scrutiny the hypothesis of a virtuous link between 
emerging industries’ competitive positioning and private equity inflows with a case 
study on life sciences in the West Holland region (the Netherlands). The first part of this 
paper is a review the literature on the evolution, locational advantages, and 
attractiveness of the emerging industries, while the second one particularizes the way in 
which an emerging industry (life sciences) has taken advantage of private equity. 
 
 
Theoretical background 
 
According to one established definition, “emerging industries are either new industrial 
sectors or existing industrial sectors that are evolving or merging into new industries. They 
are most often driven by key enabling technologies, new business models such as innovative 
service concepts, and by societal challenges that industry must address as a matter of 
survival.” (European Cluster Observatory, 2012).  
 
In the European economy, these sectors account for about 46% of all traded industry 
employment and are concentrated in approximatively 20% of European locations 
(European Cluster Observatory, 2016). The same source suggests that these sectors are 
strongest in those regions in which they have a significant portfolio of traditional sectoral 
clusters. 
 
In the current literature, a lack of information about the emerging industries exists 
because of the difficulty to study them until they become mature industries. According 
to European Cluster Observatory Report (2012), the period of time required for the 
development of such industry varies between 2 to 50 years in accordance with the 
business sector, issue confirmed through Forbes and Kirsch’s (2011) research. Because 
of their dynamism, the challenge of studying the development of these industries is more 
oriented to their relevance for economic activities of clusters, due to their cross-sectorial 
characteristics. 
 
The case for emerging industries is representative for what is disruptive and challenging 
in the contemporary business climate, with characteristics such as: 
- They are established based on new products/services as a consequence of technological 
development and socio-economical changes. 
- Usually, they are the results of cross-sector convergences on one side, and applied 
innovation and creativity, on the other side. 
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- They evolve based on intensive research and knowledge. 
- Since they are the result of traditional industries changed using new technologies in 
order to meet the new needs of customers, actors of emerging industries are more 
oriented to new opportunities and initiatives; this entrepreneurial behavior lead firstly, 
to changes in business models and secondly, to rise of new products and services, and 
even new suppliers. 
- Being based on disruptive ideas which redefine value chains and market demand, these 
industries are characterized by uncertainty due to the lack of information regarding the 
market conditions. 
- They tend to agglomerate in areas with location-specific conditions, by establishing 
linkages with other actors. 
- Because these industries require significant research and development funds, they try 
to raise private capital. Investors are attracted by the high growth potential and 
innovative approach of the industry. Venture capitalists join these companies in the early 
stages of their development and contribute to their development, and before the late-
growth stage was overpassed and they become mature on the market, investors exit, 
often by selling for mergers. (European Cluster Observatory, 2012). 
 
As this depiction suggests, two key features – location and risk associated with 
technological development – lie at the core of the business model of emerging industries. 
Let us turn to each of them to assess the key determinants in a competitive context.  
 
Location mostly relates to clusters – groups of interconnected firms, and related private 
and public actors, which activate within an industry – as drivers of competitive advantage. 
A typical organization of clusters (Porter, 1990) includes companies, suppliers, other 
related companies, customers, educational institutions, public authorities, and 
regulatory bodies, all of these being related to one specific industry.  
 
The following graph shows a general approach of clusters’ organization. 
 
 
 
Figure 1. A generic cluster environment (Porter, 1990) 
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According to Porter (2000), clusters affect business strategies in three directions, as 
follows: 
- Productivity, because of the ease of access to qualitative information and technology, 
advanced-skilled employees and suppliers, and more support through coordination with 
institutions or other related companies. 
- Innovation, because of direct competitive exposure to other companies’ performances 
and innovative approaches. The proximity of customers brings more advantages for 
companies located in clusters, compared to isolated competitors, thanks to rapid ideas-
to-market transfers.  
- New business formation, because of the linkages created between clusters’ members. 
Market opportunities are immediately seized upon in such agglomerations and new 
businesses arise taking advantages of new needs, lower entry barriers, and resources 
already available. 
 
In light of the accumulated evidence (Marshall, 1890; Porter, 1990; Schumpeter, 1939), 
clusters' development can be explained through the advantageous use of resources – 
tangible and intangible – available in particular areas, successful past experiences of 
entrepreneurs and industry specialization. Cooperation between companies, suppliers, 
customers, and institutions help clusters evolve. The local rivalry is another important 
factor which positively influences the development of such agglomerations through 
innovative improvements for changing needs in the marketplace. Since qualified labor is 
another pre-requisite for clusters' development, the whole business "community" takes 
advantage of high skills of employees and their continuous improvements. 
 
Governments have a clear interest in supporting clusters since these agglomerations are 
conducive to increasing exports and are a constant source of attracting foreign 
investments (European Cluster Observatory, 2012; InterCluster, 2010; Porter, 2000;). In 
the case of emerging industries, this support targets technological development, 
especially through regulations, improvements in infrastructure and education, or 
innovation grants oriented to specific business needs. Due to the influence of all these 
determinants, clusters develop and become stronger and stable in the market even 
during economic downturns. Delgado, Porter, and Stern (2016) conclude that strong 
clusters become more resilient to negative shocks, while the regional economy and the 
related industries take advantage of rapid recovery. 
 
More than being supported by governments, clusters quickly grow up because of the 
market conditions location-specific, therefore the quality of the economic environment 
is an important pre-requisite for their development. Porter (1990) identified four 
attributes which lead to economic development, considering the location advantages. His 
model, “The Diamond of National Advantage”, explains that there are four forces of 
nations which, individually and correlated as a system, determine the national 
competitive advantage, as follows: 
- Factor conditions; 
- Demand conditions; 
- Related and Supporting Industries; 
- Firm Strategy, Structure, and Rivalry. 
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As for the risk associated with technology development and innovation, the existing 
evidence (European Cluster Observatory, 2012; Invest Europe, 2017) points to a 
virtuous circle from emerging industries to clusters and to the private equity industry. 
In a context of optimal determinants of competitiveness, emerging industries are 
basically innovative traditional industries, which were transformed according to market 
trends; clusters are geographically agglomerations of highly innovative companies, 
while the private equity firms are the financial supporters of innovative ideas. As long as 
innovative approaches are encouraged and financed, new industries develop, while the 
traditional ones are transformed. Their growth attracts specialized suppliers and 
supports other related business sectors. The business environment is enriched due to 
new technological resources and because of increasing high skilled labor. Also, 
governments observe the power of the innovation and join this cycle through 
preferential and supporting policies. Investors receive high returns because of their 
financial and strategic support for the development of these disruptive ideas, and in the 
end, the whole economy benefits. 
 
Figure 2. Linkages between emerging industries, clusters and private equity investments 
 
 
Private equity investments help industries, and especially the emerging ones, evolve 
through capital inflow and business expertise. Joining the companies and offering 
strategic advice, they support the increased productivity of investees and innovative 
products or services, at the firm level, and enhance competitiveness at the 
macroeconomic level (Frontier Economics, 2013). Nonetheless, because each private 
investor accepts to take part of the growth plans of a company, the exit strategy is 
important, for shareholders will expect to benefit from the increasing value of their 
equity through an appropriate selling alternative. Even if companies will be sold to other 
players or will be listed on the stock exchange markets to increase their capital and to 
attract other investors, or another private equity firm will continue their development 
plans though fresh inflow of capital or the management teams/owners will take back 
their shares, the divestment method should be a win-win situation for both the company 
and the investing firm. 
 
For emerging industries, to attract private capital can be challenging because of their 
disruptive business models. Traditional financing instruments such as bank loans, 
overdrafts, credit lines, leasing or factoring, are limited for these companies because of 
the lack of collaterals (European Investment Fund, 2017), while public investors are 
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afraid of risks because of the difficulty of measuring the maturity of the industry. 
Moreover, because these industries are research-intensive industries the need of 
funding is higher compared with traditional sectors, so the companies which are active 
in emerging industries try to raise capital from private investors which are attracted by 
their high growth potential. Some alternative financing instruments available are 
venture capital (start-ups and early-stage companies financing), development capital 
(financing for the expansion of mature companies), mezzanine (equity and debt 
financing through a subordinated loan) or distressed debt (financing for the 
restructuring of troubled companies) (Seretakis, 2012). A report of the European 
Investment Fund (2018) suggests that equity as a source of financing for the SMEs of the 
Eurozone was mostly required for activities concerning companies’ development such 
as developing and launching of new products or services and hiring and training of 
employees, compared with traditional instruments.   
 
According to a report prepared by the European Savings and Retail Banking Group 
(2016), the dominant financing sources for both European and American SMEs are bank 
loans. The report emphasizes that the banking sector is smaller in the United States 
compared with the European Union, but with a large access to capital markets. According 
to British Bankers' Association (2014), in Europe, 70% of total financed amounts come 
from banks, while in the United States bank lending represents only 30% of total 
financing, (70% of American financing is supported by capital markets and other 
institutions), in 2014. Moreover, banks usually provide significant amounts of money as 
debts for private equity firms, in order to cover companies' acquisition costs, during 
buyout investments (Gilligan & Wright, 2010).  
 
The Guide on Private Equity and Venture Capital for Entrepreneurs (European Venture 
Capital Association, 2007) defines the private equity industry is defined by medium to 
long-term investments in non-listed companies, with the purpose to pursue their 
development plans and to create value for companies in critical stages of development. 
Several studies identified the economic impact of private equity investments on 
innovation, productivity, and competitiveness, as follows: 
- Impact on Innovation. By allocating funds to research and development, private equity 
firms directly help investee companies to create new products and services, compatible 
with the changing needs of customers. Together with capital, the companies also receive 
business expertise and support for their corporate governance for innovative plans. In 
order to highlight the direct effects of these capital inflows over the innovative potential 
of companies, Popov and Roosenboom (2009) studied the private equity investments 
and the number of patents developed by private equity-backed companies during 1977-
2004. Considering the patents as a proxy for innovation, they concluded that 12% of 
innovation by private companies is attributable to investments made by private equity 
firms.  
- Impact on productivity. Investments made in physical capital such as plants and 
equipment increase the companies’ productivity. Also, by improving their management, 
companies benefit from a better utilization of resources, which lead to development as 
well. The capital inflows also help companies develop and create new jobs, significantly 
contributing to economic growth. According to Frontier Economics (2013), the private 
equity investments led to the creation of approximative 5,600 new businesses each year 
in Europe, based on 2007-2012 average numbers of new companies backed by private 
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equity. The same study highlights the improved productivity of private equity-backed 
companies of 6.9 % on average, measured as EBITDA per employee. A study made by 
Kaplan and Strömberg (2009), over 1979-2007, with data from 17,171 worldwide 
companies backed by private equity firms, demonstrated the positive relationship which 
exists between the investments made by these firms and the performances of investee 
companies. 
- Impact on competitiveness. At the local level, competitiveness between companies is 
enhanced through investments for increasing productivity. By attracting capital flows, 
companies produce more and improve their offerings, gaining more market share, 
therefore they become more competitive. Also, at the international level, private equity 
investments can lead to competitiveness by supporting companies oriented to export 
activities or by helping companies to expand abroad. New or small businesses have the 
opportunity to grow by receiving capital for internationalization efforts (Frontier, 2013). 
 
Life Sciences Industry 
 
According to the World Health Organization (2005, p.5), “life sciences comprise all 
sciences that deal with living organisms, including human beings, animals and plants; a 
broad field that encompasses biology, biotechnology, genomics, proteomics, bioinformatics, 
pharmaceutical and biomedical research and techniques”. Even if the European Cluster 
Observatory (2016) considers the biopharmaceutical and the medical devices as two 
different (emerging) industries for the purpose of this study, the life sciences industry 
refers to the combination of three core business sectors such as biotechnology, 
healthcare and pharmaceuticals, following the aforementioned definition.  
 
The outcomes of these combined industries do not move forward only the medical world 
through the new solutions, but also the whole world economy, as described by the 
European Commission (2002) in its strategy, “the next wave of the knowledge-based 
economy, creating new opportunities for our societies and economies”, following the IT 
industry. 
 
At the worldwide level, the United States dominates this market in terms of number of 
companies, number of employee and funding opportunities. Compared with the 
American market, in Europe the life sciences companies face challenges especially for 
research and development funding (Ernst & Young, 2012), and the demand is increasing 
from a development phase to another, according to the European Investment Bank 
(2018) - for instance, EUR 17 million are on average required in Phase I, compared with 
EUR 169 million in Phase III. 
 
Other challenges of the industry such as global competition and healthcare reforms 
(Mihuzo Bank, 2013) force companies to build collaborative partnerships with the 
scientific and business actors.    
 
In terms of financing instruments, life sciences industry counts on grants, venture capital 
and private equity investors, public market, joint ventures and alliances and mergers and 
acquisitions (European Investment Bank, 2018). With respect to the traditional 
financing instruments, the greatest difficulty encountered by the life sciences companies 
is the lack of collaterals which guarantee the capital borrowed. Also, the cost of capital 
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may financially affect more the companies than to help them due to industry confidence 
strongly associated with a higher risk. 
 
a) Grants are, in the most cases, the first capital inflows received by the SMEs, from the 
public sector or different organizations for the research and discovery activities of the 
life sciences companies, being a very important financing source, without a repayment 
obligation, despite the small tickets offered. European Commission strongly supports the 
research activities through grants as part of the Horizon 2020 Programme (European 
Investment Bank, 2018). 
 
b) Venture Capital/Private Equity represents a major financing source for the life sciences 
companies, with an increasing interest from global fund managers oriented to this 
industry (European Investment Bank, 2018). In return for the capital invested, they 
receive control in companies by acquiring shares and may decide the entities’ 
development plans. The investee companies can take advantage in the late phase of 
development of fund managers’ industry expertise and can be strongly supported to “go 
public”. Only in Europe, according to Invest Europe’s statistics, venture capital fund 
managers invested in average more than EUR 1.2 billion per year, between 2007-2017, 
which represents in average more than 20% of venture capital investments every year. 
With respect to the backed number of companies, on average, 761 companies received 
capital, per year in the aforementioned period. 
 
A very interesting part of the venture capital investors is represented by the corporate 
venture capitals. As defined by Chesbrough (2002), these structures are corporate funds 
used to make investments, mostly financed from the balance sheet, in external 
companies, which activates in the same industry as the corporates. Their objectives are, 
on one side, strategic – to take advantage of the synergies created with the investee 
company, and, on the other side, financial – to gain attractive returns from companies 
with high potential in the industry. Such successful examples in the life sciences industry 
are M Ventures, the capital arm of Merck KGa A, Pfizer Ventures, the capital arm of Pfizer 
Inc., and Roche Venture Fund, the capital arm of Roche. 
 
Despite the high attractiveness of private equity investors to life sciences industry, 
according to an analysis made by the European Investment Bank (2018), fund managers 
still face several challenges due to the mismatch between their investment model and 
life sciences companies’ development phases, as follows: 
 - the capital demand of life sciences companies is often higher than the size of capital 
tickets invested by fund managers;   
- the average investment period of funds is smaller than the period of time required for 
a life sciences company to start the commercialization phase (5-7 years compared with 
10-12 years); 
 - strong industry expertise is required in order to assess the risk/return of such 
investments (already considered riskier, compared with other industries);  
 - lack of industry confidence due to a lack of successful companies. 
 
In the end, following the venture capital/private equity investment model oriented to 
returns, the exit route is another aspect important to be considered by the life sciences 
companies when partnering with fund managers. The most common used exits routes 
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used by fund managers, according to Gilligan and Wright (2010), are sale to corporate 
buyers, flotation on a stock market and receivership and liquidation, alongside with 
newer methods such as sale to another private equity firm or another financial 
institution, repayment of loans and preferred shares, and sale of portfolio of companies 
to other financial companies. As the analysis conducted by the European Investment 
Bank (2018) emphasized, for the life sciences companies the most preferred divestment 
method used is the first one, mostly due to increasing value of the company from the 
investment moment until the sale. A successful case was the acquisition of Kudos, a 
cancer company backed by large private equity firms, by Astra Zeneca, for USD 210 
million, in 2005. Compared with the United States, where the access to capital markets 
is significantly higher compared with Europe (European Savings and Retail Banking 
Group, 2016), initial public offerings of life sciences companies are not so numerous. 
However, there are several examples in Europe which may show the dynamics of this 
business sector. 
 
c)  Access to public market can be gained through an exit made by the previous investor 
and it represents for the companies the opportunity to raise capital from a greater 
number of investors. The greater limitation of this financing opportunity is investors' 
lack of confidence in this industry (Ernst & Young, 2016; KPMG, 2018). 
 
d) In the case of joint ventures and alliances, through a partnership with large 
multinational companies, the life sciences companies receive capital for a specific 
product, offering in exchange a stake in the development of the product and future 
revenues. It consists of payments made upfront and with a specific development 
milestone, and royalty fees if the commercialization phase starts. The greatest advantage 
for the large players is access to results of R&D activities made outside their company, 
without taking the risk of the drug development (European Investment Bank, 2018) 
 
e) Mergers and acquisitions may represent the opportunity to faster develop and 
commercialize the product, taking advantages of new financial and technological 
resources, but in the same way may be the only option for the life sciences companies 
previously backed by private equity investors, according to the aforementioned report. 
The specificity of the life sciences companies is strongly reflected in the firms’ life cycle, 
the necessary time needed for evolving from an idea to a product, and further on to 
establish on market (Mizuho Bank, 2013). Table 1 synthesizes the differences between 
the general development curve of companies and the case of life sciences, for an 
estimated period of time of approximative 12 years. If in general, a company has a 
prototype in the very first years of establishment, the life sciences companies begin with 
significant efforts for research activities. Often, these companies are created as spin-offs 
from university research laboratories (KPMG, 2018), and some specialists decide to 
continue the research in a different direction.   
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Table 1. The life cycle of companies – comparison between life sciences companies 
and general companies (European Investment Bank, 2018; European Investment 
Fund, 2018; Mihuzo Bank, 2013) 
 
 
At the European level, the largest life sciences companies are concentrated in the United 
Kingdom, Germany, France, the Netherlands, Austria, Denmark, Sweden, and Norway, 
according to the publication The Leading Life Sciences Clusters in Europe (Science 
Business, 2016). According to Biotechgate Database (2018), the United Kingdom is the 
home of 1,948 life sciences companies, followed by Germany with 1,884 companies and 
France with 1,249 companies, in 2018. Leading the pharma industry in terms of number 
of companies (121 companies), the UK has the most products in development, with a 
focus on pre-clinical and clinical research, strongly supported by private investments, 
according to KPMG’s (2018) report on “Site Selection for Life Sciences companies in 
Europe” - in 2014, 2 billion USD was raised by public companies, while the private ones 
received more than 400 million USD. Germany hosts the highest number of med-tech 
companies in Europe (531 companies), according to the aforementioned database.  Local 
incentives for innovative SME and intensity of private investments are the most 
important advantages of German companies. The amounts raised by public companies 
are very low, while the private ones achieved in 2014 the third highest level in Europe, 
following the United Kingdom and Switzerland (KPMG, 2018).  
 
 
The West Holland Life Sciences Cluster 
 
Methodological orientation 
 
To emphasize how the emerging industries, create competitive advantage, supported by 
private equity investors, an analysis of the life sciences cluster located in West Holland 
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(The Netherlands) was made. The linkages created between the cluster members 
demonstrate cluster's success, and, at the same time, industry's growth perspective.   
 
Following Porter’s (1990) general cluster map, investors – as cluster’s members – have 
a significant impact over economic growth of agglomerations, through their power of 
financing.  Their influence over emergent life sciences companies is the focus of the 
cluster map analysis. Nonetheless, we are interested in highlighting private equity 
influence over the cluster evolution through financing support offered to big industry 
players in their early stages of development. 
 
An overview of the Dutch business environment 
 
The Netherlands ranks fourth as the most competitive global economies. According to 
the Global Competitiveness Index 2017-2018 (World Economic Forum, 2018), the Dutch 
economy’s competitiveness is supported by advanced infrastructure, a strong education 
system, but mostly by an innovative environment, with a high capacity of innovation (6th 
rank out of 137).  
 
The increasing innovation of the Dutch companies can explain the growth of emerging 
industries in this country. According to the European Cluster Observatory (2016), the 
South and the North Dutch regions are significant cross-sectorial hotspots in Europe in 
emerging industries clusters: out of the top ten emerging industries in the European 
economy (advanced packaging, biopharmaceuticals, blue growth industries, creative 
industries, digital industries, environmental industries, experience industries, logistical 
services, medical devices, and mobility technologies), three of them are Dutch hubs, as 
follows: 
 
Table 2. Emerging industries in the Netherlands 
 (European Cluster Observatory, 2016) 
Emerging industries Rank (out of 10) Region City 
Blue Growth industry 5 Zuid‐Holland Rotterdam 
Creative Industries 
3 Utrecht Utrecht 
4 Noord‐Holland Amsterdam 
8 Zuid‐Holland Rotterdam 
Experience Industries 5 Noord‐Holland Amsterdam 
 
Following Porter’s (1990) diamond, the determinants factors of the Dutch competitive 
advantage are as follows:  
 
a) Factor conditions 
The Dutch labor productivity is characterized as ranking high levels at the global level 
due to high-skilled population; around 90 % of the Dutch people speak English as the 
second language. The education system is very strong in the Netherlands, especially the 
superior levels. According to the PWC (2017) Report on Doing Business in the 
Netherlands, it ranks the 3rd place globally, therefore the Dutch business environment 
is supported by the highly skilled workforce.  
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Its strategic location is important for attracting customers and for import-export 
activities – around 170 million customers within a 500-km radius, according to PWC 
(2017) Report, from London, Paris, Dusseldorf or Brussels. Also, it can easily take 
advantages of the technological developments produced by its neighboring countries, 
due to the close proximity with other strong economies such as Germany, Switzerland, the 
United Kingdom or France.  
 
Another competitive advantage of the Netherlands, from the factor conditions category, 
is the strong infrastructure built during the time for technology and innovation. The 
development of the high-tech industry in the Netherlands significantly supports the 
growth of the other industries as well, especially for the life sciences sector, which takes 
advantages of the newest bio-technologies for its products. 
 
b) Demand conditions 
The country’s development is facilitated as well by the increasing level of buyers’ 
sophisticated needs. This demand forces the producers and suppliers to offer innovative 
solutions, in order to remain in the market (PWC, 2017). 
 
The demand for innovative solutions, especially in the life sciences sector, is continuously 
increasing at the national and the international level. Because of the technological 
development, in present, it is possible to discover and to produce medical drugs or 
appliances for critical diseases, such as cancer. Therefore, the Dutch life sciences 
companies have a great potential to develop. 
 
c) Related and supporting industries 
The Netherlands is the home of more advanced industries which strongly support each 
other, such as high-tech and logistics, grouped as clusters, according to the Netherlands 
Foreign Investment Agency (2018). The life sciences sector is highly supported by these 
industries, but as well by the chemicals clusters existing in the Netherlands. In this way, 
the development of one industry positively influences the evolution of the others, 
following the general cluster theory.   
 
d) Firm strategy, structure, and rivalry 
The research and development grants allocated by the Dutch government are increasing 
from year to year, according to OECD (2018) statistics, around 2% of the GDP, facilitating 
in this way the innovation. Also, these activities are supported by special tax credits and 
other tax incentives. 
 
The economic stability of the Netherlands attracts more businesses in the country and 
more foreigners to work. To this aspect, the high competitiveness existing in the business 
environment explains the quick development of industries and clusters. 
 
Regarding the Dutch fiscal policy, there are some other competitive taxes which 
encourage entrepreneurship and attract foreign investments. The foreign companies 
take advantages of special fiscal measures and for the expats, there are created 
competitive benefits (PWC, 2017). 
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Private equity investors’ interest is increasing for the Dutch companies as well, being 
attracted by innovative ideas. According to the Invest Europe statistics, the number of 
companies backed by private equity investors increased by 30% compared with 2010 
and reached the highest level of invested amounts after the 2008 financial crisis. 
 
 
Figure 3. Private equity investments in the Dutch companies (Invest Europe, 2018) 
 
According to the same source, most attractive business sectors for venture capitalists in 
the Dutch market are biotech and healthcare and ICT (communications, computer, and 
electronics). Based on 2007-2017 data, on average, 52 life sciences companies are 
financed by venture capital funds. 
 
        
Figure 4. Venture Capital investments by business sector in the Dutch companies  
(Invest Europe, 2018) 
 
The Dutch life sciences industry 
 
According to the data provided by Biotechgate Database (2018), the industry of life 
sciences in the Netherlands is developing from year to year, based on the number of 
companies which are active in this sector (including both the companies which are 
directly involved and related companies as well) and the number of new technologies 
created each year. The following table presents a short overview of the Dutch life 
sciences industry.  
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Table 3. Overview of Life Sciences Industry in the Netherlands  
(Biotechgate Database, 2018) 
Description/Year 2014 2015 2016 2017 
No. of Dutch biotech companies  280 411 404 462 
MedTech companies 102 116 102 122 
Health Tech companies 29 40 38 39 
Medical Facilities and other public 
organizations 
116 135 128 181 
No. of other life sciences-related 
companies 
659 813 803 877 
No. of technologies developed 174 220 209 162 
 
According to Leading Life Sciences Clusters in Europe Report (Science Business, 2016), 
the Netherlands is home of approximative 63 life sciences parks, 12 universities, and 
eight university medical centers, where ca. 98,000 people are employed. 
 
One of the largest European clusters of exact sciences is located in Amsterdam Science 
Park and offers scientific opportunities for the life sciences industry, together with high 
technologies, physics, and chemistry. The cluster's development is strongly supported 
by academic and scientific institutions such as University of Amsterdam, VU University 
Amsterdam, the Academic Medical Centre Amsterdam, the Neuroscience Campus 
Amsterdam and the Pan-Amsterdam Technology Transfer Office (Science Business, 
2016). The Utrecht Science Park hosts the highest number of research institutions on a 
small area of 300-hectares and is focused on life sciences and health activities. More than 
80 businesses are located in this cluster, together with the University Medical Centre 
Utrecht and the Utrecht University. Starting with 2012, a new business park supports the 
life sciences industry in the Netherlands, the Pivot Park, located in Oss. This cluster 
developed a mix of initiatives of the government, existing companies, and private equity 
investors.  The pharmaceutical company MSD together with the municipality of the city 
and of the province, the Ministry of Economic Affairs and Ministry of Health, Welfare and 
Sports were the principal actors for this clusters' development. The financial support 
was offered by the Brabant Development Agency (BOM). Another very important life 
sciences hub in the Netherlands is the Zernike Campus Groningen, founded in the 1960s. 
In this park, there are around 150 companies, with more than 4,000 employees and 
researchers and approximative 35,000 students. The University of Groningen and the 
Hanzehogeschool supports the clusters’ knowledge (PharmInvestHolland, 2018). 
 
The life sciences and health industry’s potential can be assessed also by taking into 
consideration the Dutch Association Innovative Medicines’ initiative to transform the 
Netherlands into the “choice in Europe when it comes to research and development of 
medicines” (PharmInvestHolland, 2018). The life sciences and health industry are one of 
the nine key sectors of the Dutch economy, with more than 3,000 active companies and 
research organizations (PWC, 2017). The Dutch life sciences companies exported more 
than 37 billion EUR in 2017, out of which 25 billion EUR are revenues from 
pharmaceutical products (PharmInvestHolland, 2018). 
 
The development of this industry, not only in the Netherlands, but at the global level as 
well, started around 1590 with the invention of the microscope (Hans and Zacharias 
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Jensen), and continued with other great discoveries, scientific, for example microbiology 
(Antoni van Leeuwenhoek), human anatomy (Andreas Vesalius) or  physiology (Herman 
Boerhaave), or mainly technical, for example electrocardiogram (Willem Einthoven), or 
different medical appliances such as heart-lung machine and artificial heart (Willem 
Kolff), according to PharmInvestHolland (2018) report. 
 
According to Euro Health Consumer Index (2017), the Netherlands is the best country 
based on the healthcare system, because of the significant number of health providers, 
who act in competition, compared with other EU countries. The industry is supported by 
significant investments made in research and development, more than 2 billion EUR per 
year, according to the PWC (2017) Report. 
 
The Leiden-Rotterdam-Delft-De Hague/West Holland region is home of the leading life 
sciences cluster in the Netherlands, home of the three largest biosciences parks and more 
than 400 companies, highly supported by five research and educational institutions and 
ten R&D facilities (West Holland Life Sciences Hub). The cluster's most important 
members are as follows: 
 
1. Large industry players. The West Holland cluster hosts a significant number of large 
healthcare and pharmaceutical companies, which strongly influenced the evolution of 
the region. Some examples are Crucell, Pfizer, DSM, Janssen (part of Johnson and 
Johnson), Thermo Fisher Scientific, 3M, Siemens Healthineers and MSD. Two of the most 
important innovative solutions developed by the companies located in this cluster are 
for auto-immune diseases and the first vaccine for five childhood diseases. 
 
Big players of the life sciences industry were supported by private equity firms in their 
early stages of development, such as Crucell (in late 1990), Viroclinics Biosciences (in 
2001), and PanGenetics (in 2005). 
- Crucell, a Leiden-based company, was backed in late 1990 by the leading life sciences 
investor, Life Sciences Partners. In 2000, the company was listed on the Euronext 
Amsterdam stock exchange and later merged with another life sciences company, 
Introgene. It continued as a public company until 2011 when it was acquired by the 
global pharmaceutical company, Johnson and Johnson, and today the company is one of 
the most important actors in the vaccines industry.  
- Viroclinics Biosciences, a Rotterdam-based company, was founded in 2001 as a spin-off 
from the Department of Virology of Erasmus Medical Centre Rotterdam. It became a 
global clinical trial operation companies after it was backed by Gilde Healthcare, in 2014, 
and it continues its development with a new capital inflow from Parcom Capital after it 
changed its main shareholder in 2017.  
- PanGenetics is another example of a private equity-backed company located in the West 
Holland (Utrecht) which rapidly grew up because of private capital inflow. According to 
Business Weekly (2006), the company received two rounds of funding for its drug 
development. Soon after its establishment in 2005, a 2 million USD seed round supported 
the research activities of PanGenetics. 
 
2. Knowledge institutions. More than 6,000 students at renowned technical universities – 
TU Delft University, Leiden University, Erasmus University Rotterdam, Leiden Medical 
University Center and Erasmus Medical Center Rotterdam – are engaged in the cluster’s 
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research and development activities. For this purpose, there are ten R&D facilities 
available and three incubators.  
 
University research laboratories are often the starting point from a new life sciences 
company when some researchers decide to continue in a different direction. Only in 
Leiden, there were 35 spin-offs from academia, located now in the middle of the largest 
Dutch life sciences cluster. Harbour Antibodies BV and Quantib are only 2 successful 
cases started at Erasmus Medical Center from Rotterdam and further supported by 
private investors.  
 
3. Government. At the regional level, the local authorities support this cluster through the 
West Holland investment agency which facilitates the companies' development, together 
with fiscal incentives for innovation. The West Holland region benefits of the Health 
Ministry located in this cluster. The Association of Innovative Medicine is another 
national authority, located in the Hague, which tries to create the best conditions for 
pharmaceuticals' development and manufacturing. In the same way, HollandBio 
supports the biotechnology companies. The local authorities support the life sciences 
companies not only through direct grants but also through support to private equity 
funds. In 2010, around 35% of the funds raised came from the governmental institutions, 
according to Invest Europe (2018) statistics.  
 
The public-sector support the industry's development also through collaboration 
between the European Investment Fund (EIF) (part of the European Investment Bank) 
and the Dutch Minister of Economic Affairs for financing innovative companies. 
According to the EIF's website, the first collaboration, namely the Dutch Venture 
Initiative I, ended up in December 2016 with a total amount committed of EUR 148 
million, to 13 different venture and growth capital investment funds, out of which 5 are 
exclusively dedicated to life sciences sector. In 2016, the second program was launched 
with a focus on med-tech and life sciences alongside with ICT, clean-tech and renewable 
energy, fact that indicates the high level of innovation of these industries and how 
attractive they are for investments. Moreover, in September 2017, the Dutch Growth Co-
Investment Programme was launched to support the transition of companies from early-
stages to growth lifecycles. 
 
4. Patient organizations. For healthcare policies, the patient organizations (such as The 
Netherlands Patient and Consumer Federation (NPCF), Dutch Cancer Federation and 
other disease-specific organizations - Parkinson Association and the Epilepsy 
Association) have a crucial role, especially for the new regulations. They play the role of 
sophisticated buyers for the cluster and all the research activities are conducted in order 
to satisfy their medical needs through innovative drugs or appliances (Van de 
Bovenkamp & Trappenburg, 2011). 
 
5. Supporting industries. The logistics hub from Rotterdam significantly influences the 
pharmaceutical imports and exports, not only in this area but in the whole of Europe. 
The Port of Rotterdam and the Hague Airport are vital for the international trade with 
medical and pharmaceutical products, as well as for strong connectedness with other 
cities. High-technology companies supply life sciences companies with new solutions, for 
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instance, the 3D-printing used for medical appliances. In the same way, the chemical 
industry provides high-quality inputs for drugs development.  
 
6. Private equity investors. Because the life sciences sector's activities are high research 
intensive, the demand for funding is substantial. The product development of healthcare 
companies requires more funding rounds compared with other business sectors. In some 
cases, after years of research, these companies obtain a prototype after 4 or even 5 
investments rounds. In the West Holland region, Innovation Quarter, an economic 
development agency, supports financially the life sciences companies in this area. 
Alongside with this regional investor, there are also other private equity firms with a 
broader focus, such as Life Sciences Partners, Merck Ventures, Gilde Healthcare, and 
Forbion Capital Partners. 
 
According to Invest Europe (2018) statistics, the investments made in the West Holland 
regions, in the biotechnology and healthcare sector represents in average 21% of the 
total investments made in this industry (2007-2016 data). More than 60% of the 
investments are made in small and medium companies, in the early stages of 
development. Also, in 2016, 23,29% of the total fundraising in the Netherlands was 
raised by funds oriented to life sciences companies (Invest Europe, 2018). This inflow of 
funds, the highest since 2007, explains the increasing potential of the life sciences 
industry in the Netherlands and how attractive it has become for private investors. 
 
The local authorities support the life sciences companies not only through grants but 
also through support to private equity funds, therefore the aid is not only financial but 
also strategic because of the business expertise of these firms. Another significant 
category of investors for this industry is represented by the corporations, which can 
activate in the same sector or related, and academic institutions. The following graphs 
show the type of investors who invest in life sciences funds in the Netherlands. 
 
Figure 5.  Type of investors in the Dutch life sciences funds (Invest Europe, 2018) 
 
The number of private equity backed-companies did not change significantly from 2007 
until 2017, in average 11 companies received capital each year leading to an increased 
workforce. 
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Figure 6. Number of private equity-backed companies and economically active population in 
the West Holland region (Invest Europe, 2018) 
 
Considering the economic growth of this region, mostly endorsed to the life sciences 
industry, around 13% of the increasing welfare is justified by the private equity 
investments made in the life sciences companies clustered in the West Holland, based on 
Invest Europe and Eurostat data. 
  
Alongside with the national incentives for the development of the life sciences 
companies, the features that characterized the West Holland clusters are as follows: 
- high competitiveness within the region due to a large number of companies (the 18th 
most competitive European region according to Regional Competitiveness Index 2016); 
- very developed infrastructure (Port of Rotterdam and Rotterdam the Hague Airport) 
which assure the international trade for medical and pharmaceutical products on one 
side, and great connectedness with other cities, on the other side; 
- superior high education assures the training of researchers and advanced-skilled 
workforce. 
 
 
Conclusions 
 
Competitiveness at cluster level is enhanced through the high number of private equity-
backed companies and follow-on investments which support the research and 
development activities. In the same way, new funding rounds increased productivity at 
the company level through expansion. But mostly, the private equity investments 
support the innovation in the West Holland life sciences cluster, throughout industry 
players, related-companies and governmental initiatives. 
 
As this paper has emphasized, the success of the West Holland Life Sciences cluster is 
explained by a local context of strong cooperation between (1) large industry players, 
(2) knowledge institutions, (3) government and (4) patient organizations, (5) private 
equity investors and (6) supporting industries, enhanced by the high competitive level 
within the region due to the large number of companies (the 18th most competitive 
European region according to European Commission, 2016).  
 
The private capital inflows in this area are expected to increase in the following years 
due to the relocation of the European Medicine Agency from London to Amsterdam. In 
the same way, some big industry players may change their operational activities in the 
European Union to take advantages of the community benefits, therefore the West 
0
10
20
2.30
2.32
2.34
2.36
2.38
2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
N
u
m
b
er
 o
f 
co
m
ap
an
ie
s
m
ill
io
n
 p
er
so
n
s
Active population
Financial Crisis
Management Dynamics in the Knowledge Economy | 549 
Vol.6 (2018) no.4, pp.531-551; www.managementdynamics.ro 
Holland can become a better option for private equity investors instead of the United 
Kingdom, and a more successful life sciences cluster at the international level. 
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